Generic Name: Revatio

What is Revatio?

See the WARNING box above. Tell your health care provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of zidovudine.

To learn more about possible side effects of zidovudine, read the drug label or package insert or talk to your health care provider or pharmacist. Protect zidovudine capsules from moisture. Keep zidovudine in the container that it came in and keep the container tightly closed. Do not use zidovudine if the original seal over the bottle opening is broken or missing. More information about zidovudine is available: The zidovudine drug label, from DailyMed.

The Patient Counseling Information section of the label includes information for people taking zidovudine capsules and syrup. Recommendations on the off-label HIV-related use of zidovudine from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention CDCthe National Institutes of Health NIHand the HIV Medicine Association of the Infectious Diseases Society of America IDSA-HIVMA.

Skip to main content U. What should I tell my health care provider before taking zidovudine.

Retrovir is a nucleoside reverse transcriptase inhibitor NRTI. In September 2005, the FDA approved a generic version of zidovudine. Coformulations Retrovir is included in the combination drugs Trizivir Retrovir, Epivir, and Ziagen and Combivir Retrovir and Epivirboth of which are taken twice daily.

Dose The recommended dose for Retrovir in adults is 300 mg twice a day. For more information, call 866. Side Effects and Toxicity Retrovir can suppress bone marrow production of blood cells, resulting in anemia or neutropenia. In patients with low neutrophil counts less than 1000 or hemoglobin levels less than 9. Special care should be taken when administering the drug to patients with advanced HIV disease or other conditions characterized by anemia or neutropenia. Lactic acidosis and severe hepatomegaly enlarged liver with steatosis fatty liver is rare, but potentially fatal, and has been associated with NRTI use.

Additionally, some complaints of gastrointestinal intolerance pain, nausea and diarrheaheadache, insomnia, and asthenia weakness have been documented. Myopathy muscle wasting and myositis muscle inflammationsimilar to that produced by HIV itself, have been associated with prolonged use of Retrovir. As a class, NRTIs have been implicated in damage to mitochondrial DNA and may therefore play a role in the development of lipodystrophy fat accumulation and fat atrophy.

Drug Interactions Because of blood cell hematologic toxicity, caution should be used when co-administering Retrovir with bone marrow suppressive agents or interferon alpha.

How should I take Revatio?

The manufacturer of Retrovir is conducting studies to see if Retrovir can be taken once a day, but these have not yet been completed. The dose depends on a baby's size or a child's weight.

If you are caring for a child who is HIV-positive and has been prescribed Retrovir, be sure that you understand the correct dose to give the child. As a child grows, the dose of Retrovir will need to be increased on a regular basis. Retrovir should not be taken alone as monotherapy or with just one other anti-HIV drug.

What should I avoid while taking Revatio?

There were no other drug-related tumours observed in either sex of either species. In addition, two transplacental carcinogenicity studies have been conducted in mice.

One study, by the US National Cancer Institute, administered zidovudine at maximum tolerated doses to pregnant mice from day 12 to 18 of gestation. Treatment related findings were limited to late-occurring vaginal epithelial tumours, which were seen with a similar incidence and time of onset as in the standard oral carcinogenicity study.

The second study thus provided no evidence that zidovudine acts as a transplacental carcinogen. It is concluded that the transplacental carcinogenicity data from the first study represents a hypothetical risk, whereas the reduction in risk of maternal transfection of HIV to the uninfected child by the use of zidovudine in pregnancy has been well proven.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. A 10 ml oral-dosing syringe is included in the pack, with an adaptor, which should be fitted to the bottle before use.

Revatio side effects

It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to Retrovir. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your health care provider for complete information about the risks and benefits of using Retrovir. Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine.

This is only a brief summary of general information about this medicine.

Common Revatio ide effects may include:

  • This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition.

  • About Site Map Feedback Subscribe Donate Disclaimer HIV InSite is a project of the UCSF Center for HIV Information.

  • Rare adverse reactions to zidovudine include developing an enlarged fatty liver and raised levels of lactic acid.

  • There were no other drug-related tumours observed in either sex of either species.

To explain how AZT works, we need to first tell you some information about HIV. Since AZT inhibits, or reduces the activity of this enzyme, this drug causes HIV-infected cells to produce fewer viruses. Combinations such as this are called antiretroviral therapy, or ART. For more information on ART, see CATIE's Your Guide to HIV Treatment.

Where can I get more information?

  • Human Data: Based on prospective reports to the APR of over 13,000 exposures to zidovudine during pregnancy resulting in live births including over 4,000 exposed in the first trimesterthere was no difference between the overall risk of birth defects for zidovudine compared with the background birth defect rate of 2.

  • For patients experiencing pronounced anemia or other severe zidovudine-associated events while receiving chronic administration of zidovudine and some of the drugs e.